Trial Profile
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Crizotinib (Primary) ; Savolitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms PAPMET
- 11 Apr 2024 Planned End Date changed from 4 Jan 2023 to 12 Dec 2024.
- 06 Jun 2023 Results assessing outcomes stratified by histologic subtype per central review, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium